Narrow DCIS Margins May Not Always Warrant Reexcision
-
By
-
Andrea Surnit
-
July 20, 2026
-
6 min
By
Andrea Surnit
July 20, 2026
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
July 14, 2026
A randomized trial found similar short-term morbidity and 12-month functional outcomes with both approaches, while highlighting the need to balance perfusion with a tension-free anastomosis.
July 15, 2026
Proteomic biomarkers improve short-term lung cancer risk assessment.
June 1, 2026